The number of included studies could not be verified due to the absence of tabulated data relating to lumboperitoneal shunts (see below). The number of included patients was 344.
Optic nerve sheath decompression (252 patients; 423 eyes): Data from seven retrospective case series (optic nerve sheath decompression was the primary surgery in 90% of cases) showed an overall vision improvement of 80% (339 eyes). In a subgroup of 18 chronic patients, an improvement of 66% (21 eyes) was noted.
Intracranial venous sinus stents (17 patients): Vision was improved or resolved in 47% of patients (n=8). Eight patients had resolution of papilledema (47.1%) and one was improved (5.9%). Headaches were resolved in eight patients (47.1%).
Ventriculoperitoneal shunts (31 patients): Vision was improved in 38.7% of patients (n=12). There were 17 reported cases of resolved papilledema, and headaches were resolved or improved in 2 patients.
Lumboperitoneal shunts (44 patients): Vision signs and symptoms were resolved in 44.6% of patients (n=20). Papilledema was resolved in 10 patients (22.7%) and improved in seven patients (15.9%). Headaches were resolved in eight patients (18.2%) and improved in 12 patients (27.3%). The paper did not present a table of results for lumboperitoneal shunts; a table of response to chemotherapy in optic pathway gliomas was available in its place.
According to the summary table, visual worsening was present in 0% of patients after ventriculoperitoneal and optic nerve sheath decompression, approximately 6% after stent placement, and approximately 5% after lumboperitoneal shunt placement. However, the text stated that 11% of patients had worse visual acuity or visual field after optic nerve sheath decompression.